Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and Its Inhibition by the IL-12 p40 Subunit Homodimer

Journal of Immunology

Volumn 159, Issue 1, 1997, Pages 351-359

  Chen, Ling ^a,c   Chen, Dongshu ^c   Block, Ellen ^c   O'Donnell, Michael ^c   Kufe, Donald W ^c   Clinton, Steven K ^b,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12;

ADENOVIRUS; ANIMAL; ARTICLE; BIOSYNTHESIS; BLADDER TUMOR; CARCINOMA; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; IMMUNITY; IMMUNOLOGY; MOUSE;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CARCINOMA; DNA, COMPLEMENTARY; GENE THERAPY; GENETIC VECTORS; IMMUNITY; INTERLEUKIN-12; MICE; NEOPLASMS, EXPERIMENTAL; TRANSFECTION; URINARY BLADDER NEOPLASMS;

EID: 0031178963     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, R. Loudon, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170:827.
2. Stern, A. S., F. J. Podlaski, J. D. Hulmes, Y. E. Pan, P. M. Quinn, A. G. Wolitzky, P. C. Familletti, D. L. Stremlo, T. Truitt, R. Chizzonite, and M. K. Gately. 1990. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. USA 87:6808.
3. Robertsen, M. J., and J. Ritz. 1996. Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist 1:88.
4. Merberg, D. M., S. F. Wolf, and S. C. Clark. 1992. Sequence similarity between NKSF and the 1L-6/G-CSF family. Immunol. Today 13:77.
5. Gearing, D. P., and D. Cosman. 1991. Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor. Cell 66:9.
6. Schoenhaut, D. S., A. O. Chua, A. G. Wolitzky, P. Quinn, C. Dwyer, W. McComas, P. C. Familletti, M. K. Gately, and U. Gubler. 1992. Cloning and expression of murine IL-12. J. Immunol. 148:3433.
7. Wolf, S. F., P. A. Temple, M. Kobayashi, D. Young, M. Dicig, L. Lowe, R. Dzialo, L. Fitz, C. Ferenz, R. M. Hewick, K. Kelleher, S. H. Herrmann, S. C. Clark, L. Azzoni, S. H. Chan, G. Trinchieri, and B. Perussia. 1991. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J. Immunol. 146:3074.
8. Trinchieri, G. 1994. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes, Blood 84:4008.
9. Gubler, U., A. O. Chua, D. S. Schoenhaut, C. M. Dwyer, W. McComas, R. Motyka, N. Nabavi, A. G. Wolitzky, P. M. Quinn, P. C. Familletti, and M. K. Gately, 1991. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc. Natl. Acad. Sci. USA 88:4143.
10. Ling, P., M. K. Gately, U. Gubler, A. Stern, P. Lin, K. Hollfelder, C. Su, Y. Pan, and J. Hakimi. 1995. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J. Immunol. 154:116.
11. Mattner, F., S. Fischer, S. Guckes, S. Jin, E. Schmitt, E. Rude, and T. Germann. 1993. The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer. Eur. J. Immunol. 23:2202.
12. D'Andrea, A., M. Rengaraju, N. M. Valiante, J. Chehimi, M. Kubin, M. Aste, S. H. Chan, M. Koayashi, D. Young, E. Nickbarg, R. Chizzonite, S. F. Wolf, and G. Trinchieri, 1992. Production of natural killer cell stimulatory factor (interleukin-12) by peripheral blood mononuclear cells. J. Exp. Med. 176:1387.
13. + T cells. J. Immunol. 154:5071.
14. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulutory functions that bridge innate resistance and antigen-specific adaptive immunity. Anna. Rev. Immunol. 13:251.
15. Trinchieri, G. 1995. Interleukin-12 and interferon-γ: do they always go together? Am. J. Pathol. 147:1534.
16. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1223.
17. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. Nalesnik, M. Brunda, M. Gately, S. Wolf, R. Schreiber, W. Storkus, and M. Lotze. 1994. IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153:1697.
18. Noguchi, Y., E. C. Richards, Y.-T. Chen, and L. J. Old. 1995. Influence of interleukin-12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 92:2219.
19. Brunda, M. J., L. Luistro, J. A. Hendrzak, M. Fountoulakis, G. Garotta, and M. K. Gately. 1995. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J. Immunother. 17:71.
20. Bree, A. G., F. J. Schlerman, M. D. Kaviani, R. C. Hastings, S. L. Hitz, and S. J. Goldman. 1994. Multiple effects on peripheral hematology following administration of recombinant human interleukin-12 to nonhuman primates. Biochem. Biophys. Res. Commun. 204:1150.
21. Sarmiento, U. M., J. H. Riley, P. A. Knaack, J. M. Lipman, J. M. Becker, M. K. Gately, R. Chizzonite, and T. D. Anderson. 1994. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). Lab. Invest. 71: 862.
22. Atkins, M. B., M. Robertson, M. S. Gordon, M. T. Lotze, J. DuBois, J. Ritz, A. Sandier, H. D. Edington, and M. L. Sherman. 1996. Phase I evaluation of intravenous recombinant human interleukin-12 (rhIL-12) in patients with advanced malignancies. J. Clin. Oncol. 15:270 (Abstr, 718).
23. Cohen, J. 1995. IL-12 deaths: explanation and a puzzle. Science 270:908.
24. Tahara, H., L. Zitvogel, W. J. Storkus, H. G. Zeth, T. G. McKinney, R. D. Schreiber, U. Gubler, P. D. Robbins, and M. T. Lotze. 1995. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154:6466.
25. Chen, L., D. Chen, Y. Manome, Y. Dong, H. Fine, and D. Kufe, 1995. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J. Clin. Invest. 96:2775.
26. Graham, F. L., and L. Prevec. 1991. Manipulation of adenovirus vectors. In Gene Transfer and Expression Protocols. E. J. Murray, ed. Humana Press, Clifton, NJ.
27. Summerhayes, I. C., and L. M. Franks. 1979. Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J. Natl. Cancer Inst. 62:1017.
28. Coligan, J. E., A. M. Kruisbeck, D. H. Margulies, E. M. Sherach, and W. Strober. 1991. Current Protocols in Immunology. Green and Wiley-Interscience, New York.
29. Dialynas, D. P., Z. S. Quan, K. A. Wall, A. Pierres, J. Quintans, M. R. Loken, M. Pierres, and F. W. Fitch. 1983. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody, GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J. Immunol. 131:2445.
30. Sarmiento, M., A. L. Glasebrook, and F. W. Filch. 1980. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J. Immunol. 125:2665.
31. (-) mouse: a model to study differentiation of murine NK cells. J. Immunol. 137:3742.
32. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, V. Jackson, L. Brose, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor simulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539.
33. Steel, R. G. D., and J. H. Torrie. 1980. Principles and Procedures of Statistics: A Biometrical Approach, 2nd Ed. McGraw-Hill Book Company, New York.
34. Scheffé, H. 1953. A method for judging all contrasts in the analysis of variance. Biometrika 40:87.
35. Lee, E. T. 1992. Statistical Methods for Survival Data Analysis, John Wiley & Sons, New York.
36. Jang, S. K., M. V. Davies, R. J. Kaufman, and E. Wimmer. 1989. Initiation of protein synthesis by internal entry of ribosomes into the 5′ nontranslated region of encephalomyocarditis virus RNA in vivo. J. Virol. 63:1651.
37. Kato, K., O. Shimozato, K. Hoshi, H. Wakimoto, H. Hamada, H. Yagita, and K. Okumura. 1996. Local production of the p40 subunit of interleukin-12 suppresses T-helper 1-mediated immune responses and prevents allogeneic myoblast rejection. Proc. Natl. Acad. Sci. USA 93:9085.
38. Bramson, J., M. Hitt, W. S. Gallichan, K. L. Rosenthal, J. Gauldie, and F. L. Graham. 1996. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum. Gene Ther. 7:333.
39. Meko, J. B., J. H. Yim, K. Tsung, and J. A. Norton. 1995. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin-12. Cancer Res. 55:4765.
40. Zitvogel, L. H. Tahara, Q. Cai, W. J. Storkus, G. Muller, S. F. Wolf, M. Gately, P. D. Robbins, and M. T. Lotze. 1994. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum. Gene Ther. 5:1493.
41. Hunter-Mayor, S., M. O'Donnell, A. Szilvasi, and S. K. Clinton. 1995. Combination of interleukin-12 and bacille Calmette-Guerin immune therapy of bladder carcinoma in mice. Proc. Am. Assoc. Cancer Res. 36:480 (Abstr. 2860).
42. Gabrilovich, D. I., H. L. Chen, K. R. Girgis, H. T. Cunningham, G. M. Meny, S. Kadaf, D. Kavanaugh, and D. P. Carbone. 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2:1096.
43. Colombo, M. P., M. Vagliani, F. Spreafico, M. Parenza, C. Chiodoni, C. Melani, und A. Stoppacciaro, 1996. Amount of interleukin-12 available at the tumor site is critical for tumor regression. Cancer Res. 56:2531.
44. Bramson, J. L., M. Hitt, C. L. Addison, W. J. Muller, J. Gauldie, and F. L. Graham. 1996. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12, Hum. Gene Ther. 7:1995.
45. Tahara, H., H. J. Zeh, W. J. Storkus, I. Pappo, S. C. Watkins, U. Gubler, S. Wolf, P. D. Robbins, and M. T. Lotze. 1994. Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth und induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54:182.
46. Gillessen, S., D. Carvajal, P. Ling, F. J. Podlaski, D. L. Stremlo, P. C. Familletti, U. Gubler, D. H. Presky, A. Stern, and M. K. Gately. 1995. Mouse interleukin-12 (1L-12) p40 homodimer; a potent IL-12 antagonist, Eur. J. Immunol. 25:200,
47. Snijders, A., C. M. Hilkens, T. Krann, M. Engel, L. A. Aarden, and M. L. Kapsenberg. 1996. Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit. J. Immunol. 156:1207.
48. Leonard, J., K. E. Waldburger, and S. J. Goldman. 1995. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. 181:381.
49. Trembleau, S., T. Germann, M. K. Gately, and L. Adorini. 1995. The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol. Today 16:383.